Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Relapsed/Refractory Follicular Lymphoma
NCT05467943Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tazemetostat in follicular lymphoma (FL) (2 cohorts), sponsored by HUTCHMED. Primary endpoint: Objective Response Rate at 22 months. Started Jul 2022; status: completed.
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05467943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467943.